HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterization of therapeutic candidates for various fibrotic diseases, including cancer-associated fibrosis.

For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase 1b trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting treatments based on the structural features of uncommon EGFR mutations.

BUFFALO, NY — October 16, 2026 — A new research paper was published in Volume 13 of Oncoscience on September 24, 2026, titled “Investigating the role of 3D goggles in optimising time during deep-inspiratory breath-hold radiotherapy: A randomised study.”

WPI researchers, who are developing a tool to analyze skin images for signs of skin cancer, have finished third in an international artificial intelligence (AI) competition aimed at improving early diagnosis of melanoma, a potentially lethal type of skin cancer.

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by high mortality and limited treatment options. A new review published in the Chinese Medical Journal provides a comprehensive overview of how two key cancer hallmarks—epigenetic regulation and metabolic reprogramming—interact to drive HCC progression. The review highlights the bidirectional crosstalk between these processes and explores how targeting this axis could open new avenues for therapy.

Protein glutamylation is a reversible post-translational modification regulating protein activity, stability, localization, and interactions. Once considered part of the tubulin code, it is now recognized as a broader signaling mechanism. This review summarizes TTLL/CCP enzymes; roles in cilia, neurodevelopment, cell division, and cytoskeleton; and nontubulin substrates including cGAS, KLF4, IL-7Rα, BAP1, TAB1, and YAP1, which affect immunity, cell fate, metabolism, tumor progression, and immune evasion. It proposes glutamylation as a versatile signaling-related PTM and discusses therapeutic and biomarker opportunities.